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Abstract
Aims Growth differentiation factor (GDF)-15 mirrors inflammation and oxidative stress in cardiovascular diseases. Brain na-
triuretic peptide (BNP) is associated with cardiomyocyte stretch in heart failure (HF). The objective of this study was to eval-
uate the prognostic impact of plasma GDF-15 and BNP in acute HF.
Methods and results We studied a subgroup of patients prospectively recruited in an acute HF registry (follow-up: 2 years;
endpoint: all-cause mortality). Cox regression multivariate models were built to study the association of GDF-15 and mortality.
Further cross-classification according to discharge GDF-15 (mean) and BNP (mean) and association with mortality was studied.
We studied 158 patients: seventy-nine were male, mean age was 75 years, 55.1% had left ventricular ejection fraction < 40%,
mean discharge BNP was 1000 pg/mL, and mean GDF-15 was 3013 ng/mL. Higher BNP and GDF-15 predicted 2-year mortality.
Patients with GDF-15 ≥ 3000 ng/mL had a multivariate adjusted 2-year death risk of 1.86 (1.08–3.18). Patients discharged
with both BNP and GDF-15 above the mean had an adjusted hazard ratio of 4.33 (2.07–9.06) when compared with those with
both <mean.
Conclusions Higher GDF-15 associated with worse prognosis in acute HF independently of BNP. When both biomarkers
GDF-15 and BNP were elevated at discharge, the 2-year mortality risk increased over four-fold. Biomarkers related to different
pathophysiological pathways can provide incremental prognostic information in acute HF.
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Introduction
Biomarkers reflect biological processes and can provide objec-
tive and accurate information with diagnostic and prognostic
significance. Their use has emerged as a promising and cost-
effective diagnostic method to facilitate therapeutic decision-
making in acute heart failure (HF).1 Growth differentiation
factor 15 (GDF-15) is a member of the transforming growth fac-
tor ? cytokine superfamily that is highly expressed in inflamma-
tory states.2–4 There is evidence that GDF-15 levels are elevated
in cardiovascular diseases and in HF.5,6 Previous observations
have shown that GDF-15 is associated with prognosis in chronic
HF irrespective of ejection fraction.6,7 B-type natriuretic pep-
tide (BNP) is a robust biomarker with prognostic significance
in all spectrum of HF severity and in acute and chronic HF.8–12
GDF-15 mirrors inflammatory stress and BNP mirrors mainly
wall stretch. We aimed to evaluate the correlation between
these two biomarkers and to evaluate if GDF-15, by reflecting
a different pathophysiological pathway, provided incremental
prognostic information to BNP in acute HF.
Methods
We studied a subgroup of patients prospectively recruited as
part of an acute HF registry that was conducted in the Inter-
nal Medicine Department of São João Hospital Center be-
tween January 2009 and December 2010. All patients
admitted with the primary diagnosis of acute HF were eligible
for inclusion in the registry; patients with acute coronary
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syndrome were excluded, as well as those patients whose
symptoms were ultimately attributed, by the attending physi-
cian, to causes other than HF. Patients with no structural or
function echocardiographic abnormalities were also excluded
from the registry. Both de novo and worsening chronic HF as
well as patients with systolic dysfunction and those with HF
with preserved ejection fraction were included. As part of
the registry’s protocol, a complete physical examination at
admission and in the discharge day was performed to all pa-
tients, and patients were drawn a fasting venous blood sam-
ple within the first 48 h of hospital admission as well as in the
discharge day. BNP determination is a routine laboratory pro-
cedure in our hospital; an Abbott chemiluminescent micro-
particle immunoassay (two-step immunoassay) is used.
Serum creatinine was measured using conventional methods
with an Olympus AU5400® automated clinical chemistry ana-
lyzer (Beckman-Coulter®, Krefeld, Germany). Haemoglobin
was obtained using an automated blood counter Sysmex®
XE-5000 (Sysmex Europe GmbH, Norderstedt, Germany).
GDF-15 was measured by ELISA (Quantikine Human GDF-15
immunoassay). Dilutions (1/4 to 1/8) were performed to
obtain values within the analytic range of the kit the assay
had a 7% of coefficient of variation.
An echocardiogram was performed to all patients during
hospitalization. Left ventricular ejection fraction ≥50% was
considered preserved systolic function. The patient’s treat-
ment strategy, timing of discharge, and discharge medication
were at the discretion of the attending physician. Physicians
treating acute HF patients were aware of the ongoing regis-
try. The 2008 European Society of Cardiology guidelines were
used for the diagnosis of HF.13
The registry’s protocol conformed to the ethical guidelines
of the Declaration of Helsinki, and it was approved by the lo-
cal ethics committee.
GDF-15 was measured at hospital discharge in a subgroup
of consecutive patients. Patients were followed up to 2 years,
and the endpoint under analysis was all-cause mortality.
Statistical analysis
A Spearman correlation coefficient was used to study the cor-
relation between GDF-15 and BNP, age, creatinine, C-reactive
protein, and haemoglobin. Patients with discharge GDF-15
below and above the median value were compared: χ2 test
for categorical variables, Student’s t-test to compare continu-
ous variables, and a Mann–Whitney U-test when continuous
variables had a highly skewed distribution.
A Cox regression analysis was used to study the prognostic
impact of GDF-15 and BNP. GDF-15 was analysed both as a
continuous and as a categorical variable—dichotomized ac-
cording to the mean. If was first tested and confirmed that
there was a stepwise increase in mortality risk with increasing
values of GDF-15. Multivariate models were built to study the
independent association of GDF-15 with mortality. Variables
entering the model were variables differently distributed ac-
cording to GDF-15: age, haemoglobin, creatinine, C-reactive
protein, New York Heart Association (NYHA) class, and BNP;
gender and left ventricular systolic dysfunction also entered
the model. A second model was built also considering
evidence-based HF medications; however, this is not the final
model presented because the number of events does not
support so many covariates without risk of overfitting. Pa-
tients were further cross-classified according to discharge
GDF-15 (mean) and discharge BNP (mean) in three groups:
those with both discharge GDF-15 and BNP ≥ mean, those
with both discharge GDF-15 and BNP < mean (reference cat-
egory), and those with only one of BNP or GDF-15 above the
mean (BNP ≥mean, but not GDF-15, and GDF-15 ≥mean, but
not BNP). Independent association with mortality was also
studied for this dummy-coded variable.
Results
We studied 158 patients discharged after an acute HF epi-
sode. Seventy-nine (50%) were male, mean age was 75 years,
87 (55.1%) had left ventricular ejection fraction <40%, mean
discharge BNP was 1000.2 pg/mL, and mean (standard devia-
tion) discharge GDF-15 was 3013.3 (1643.0) ng/mL. During
the 2-year follow-up, 71 patients (44.9%) died.
Table 1 shows patients’ characteristics and comparison be-
tween patients with GDF-15 <3000 and ≥3000 ng/mL (ap-
proximately the mean value). Patients with higher GDF-15
(≥3000 ng/mL) were significantly older and had higher BNP,
higher creatinine and C-reactive protein, and lower
haemoglobin; they were discharged on higher NYHA class
and less medicated with beta-blockers. No differences were
reported concerning gender, co-morbidities, ischaemic
aetiology of HF, and left ventricular ejection fraction. More
patients with elevated discharge GDF-15 died in the 2-year
follow-up. GDF-15 correlated positively with age (ρ = 0.27),
BNP (ρ = 0.36), creatinine (ρ = 0.51), and C-reactive protein
(ρ = 0.28) and negatively with haemoglobin (ρ = 0.305).
Patients with discharge BNP ≥ 1000 pg/mL had an: age-,
gender-, left ventricular systolic dysfunction-, discharge NYHA
class-, creatinine-, C-reactive protein-, haemoglobin-, and
GDF-15; independent risk of 2-year mortality of 2.26 (95%
confidence interval: 1.30–3.94), and the age-, gender-, left
ventricular systolic dysfunction-, discharge NYHA class-, creat-
inine, C-reactive protein-, haemoglobin-, and BNP-adjusted
risk for GDF-15 ≥ 3000 ng/mL was 1.86 (95% confidence
interval:1.08–3.18). Table 2 shows the final multivariate
model. Figure 1 shows the Kaplan–Meier survival curves in
patients discharged with GDF-15 < 3000 ng/mL and those
with higher GDF-15 values. When BNP and GDF-15 were
analysed as continuous variables, similar independent
1018 P. Bettencourt et al.
ESC Heart Failure 2018; 5: 1017–1022
DOI: 10.1002/ehf2.12301
associations with mortality were obtained (Table 3). When
angiotensin-converting enzyme inhibitors and/or angiotensin
receptor blockers, beta-blockers, and mineralocorticoid re-
ceptor antagonists were included in the model, both GDF-
15 and BNP remained independently associated with the out-
come (data not shown).
Patients discharged with both BNP and GDF-15 above the
mean had a multivariate adjusted hazard ratio of 2-year
death of 4.33 (2.07–90.6), P < 0.001 when compared with
the reference category (both BNP and GDF-15 below the
mean). Patients with only one of the variables above the
mean had a hazard ratio of 2-year mortality of 1.76
(0.99–3.14), P = 0.06 (Table 4). Results were similar if
evidence-based HF therapy was included in the final model.
Figure 2 shows the Kaplan–Meier survival curves in patients
with both GDF-15 and BNP values at discharge above the
mean, those with both parameters below the mean at dis-
charge, and those with only one of the parameters above
the mean at hospital discharge.
Discussion
Our results provide evidence that a multi-marker approach to
stratify patients after an acute HF episode based on different
biomarkers that mirror diverse physiopathological systems in
HF is promising. These results give subtract to the growing
concept that the development of strategies based on individ-
ual characteristics have the potential to better tailor HF
therapy in an individual level. In our acute HF population, we
observed that patients with higher GDF-15 had an almost
double long-term mortality when compared with patients
with lower levels; patients with higher BNP had a more than
double mortality risk; and patients with both biomarkers
above the median hadmore than a four-fold higher death risk.
GDF-15 is a marker of inflammation; it is a member of the
transforming growth factor family, which is overexpressed in
response to myocardial stress.14 GDF-15 expression is in-
duced by myocardial stress and remodelling and is expressed
in myocytes in response to cardiac ischaemia and pressure
Table 1 Comparison between acute HF patients with HFrEF and HFpEF
Characteristics
All patients
(n = 158)
GDF-15 <
3000 ng/mL (n = 91)
GDF-15 ≥
3000 ng/mL (n = 67) P-value
Male, n (%) 79 (50.0) 46 (50.5) 33 (49.3) 0.87
Age, mean (SD) 75 (13) 73 (14) 78 (12) 0.02
Atrial fibrillation, n (%) 86 (54.4) 51 (56.0) 35 (52.2) 0.71
Diabetes mellitus, n (%) 57 (36.1) 32 (35.2) 25 (37.3) 0.78
Arterial hypertension history, n (%) 114 (72.2) 64 (70.3) 50 (74.6) 0.52
Ischaemic aetiology, n (%) 74 (46.8) 40 (44.0) 34 (50.7) 0.40
Left ventricular systolic function < 40% 87 (55.1) 57 (57.1) 35 (52.2) 0.54
Discharge NYHA ≥III, n (%) 30 (19.0) 11 (12.1) 19 (28.4) 0.009
Discharge haemoglobin (g/dL), mean (SD) 12.4 (2.1) 12.8 (1.7) 12.0 (2.4) 0.02
Discharge creatinine (mg/dL), mean (SD) 1.44 (0.71) 1.19 (0.36) 1.77 (0.92) <0.001
Discharge BNP (pg/mL), median (IQR) 599.6 (260.2–1205.4) 444.1 (209.2–869.0) 800.7 (390.8–1513.8) 0.001
Discharge high-sensitivity C-reactive
protein (mg/L), median (IQR)
12.3 (5.5–24.6) 10.7 (4.5–21.4) 15.5 (9.2–28.6) 0.003
Acetylsalicylic acid, n (%) 92 (58.2) 52 (57.1) 40 (59.7) 0.78
Statin, n (%) 97 (61.4) 55 (60.4) 42 (62.7) 0.82
Beta-blocker at discharge, n (%) 115 (72.8) 72 (79.1) 43 (64.2) 0.04
ACE-I and/or ARB at discharge, n (%) 134 (84.8) 79 (86.8) 55 (82.1) 0.41
Mineralocorticoid receptor antagonists, n (%) 44 (27.8) 24 (26.4) 20 (29.9) 0.63
2-year death 71 (44.9) 32 (35.2) 39 (58.2) 0.004
ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BNP, B-type natriuretic peptide; GDF-15, Growth
differentiation factor 15; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection
fraction; IQR, interquartile range; NYHA, New York Heart Association; SD, standard deviation.
Table 2 Association of discharge BNP and discharge GDF-15 level with 2-year mortality: multivariate model
HR (95% CI) P-value
Discharge GDF-15 ≥ 3000 ng/mL 1.86 (1.08–3.18) 0.02
Discharge BNP ≥1000 pg/mL 2.26 (1.30–3.94) 0.004
Age (per year) 1.01 (0.99–1.04) 0.30
Male 1.52 (0.88–2.65) 0.14
Discharge creatinine (per mg/dL) 1.06 (0.74–1.52) 0.76
Discharge haemoglobin (per g/dL) 0.91 (0.80–1.02) 0.12
Discharge C-reactive protein (per mg/L) 1.00 (0.99–1.01) 0.73
Left ventricular systolic dysfunction<40% 0.72 (0.40–1.29) 0.27
Discharge NYHA class ≥III 0.84 (0.45–1.57) 0.58
BNP, B-type natriuretic peptide; CI, confidence interval; GDF-15, growth differentiation factor 15; HR, hazard ratio; NYHA, New York Heart
Association.
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overload.15 Elevated levels of GDF-15 have been reported in
acute coronary syndromes and chronic HF.6,7,16
In our study, we simultaneously measured GDF-15 and
BNP in acute HF. We provide evidence of the incremental
prognostic utility of GDF-15 over and on top of BNP. The ad-
ditional prognostic value suggests that beyond the haemody-
namic wall stress (BNP), the inflammatory stress (GDF-15)
may play an important role in acute HF. Our study sample
represents a real-world acute HF population of elderly pa-
tients with elevated prevalence of HF with preserved ejection
fraction and high co-morbidity burden.
In chronic HF, there is wide evidence showing the indepen-
dent prognostic value of GDF-15 in patients with preserved
and reduced ejection fraction.6,7,16–18 The prognostic value
of GDF-15 has first been observed by Kempf et al. who mea-
sured circulating levels of GDF-15 in 455 chronic HF patients.
Increasing GDF-15 levels were associated with increasing HF
severity. Two-year mortality increased across GDF-15 quar-
tiles (10.0%, 9.4%, 33.4%, and 56.2%, respectively,
P < 0.001). Even after multivariate adjustment including for
N terminal pro brain natriuretic peptide, GDF-15 remained
an independent predictor of mortality.6 Further data from
the Val-HeFT (Valsartan Heart Failure Trial) study support
the use of GDF-15 in chronic HF.16 In Val-HeFT, GDF-15 was
Table 3 Association of discharge BNP and discharge GDF-15 level (analysed as continuous variables) with 2-year mortality: multivariate
model
HR (95% CI) P-value
Discharge GDF-15 (per 100 ng/mL) 1.02 (1.00–1.03) 0.04
Discharge BNP (per 100 pg/mL) 1.01 (1.00–1.02) 0.04
Age (per year) 1.02 (0.99–1.04) 0.12
Male 1.59 (0.91–2.75) 0.10
Discharge creatinine (per mg/dL) 1.11 (0.77–1.59) 0.59
Discharge haemoglobin (per g/dL) 0.88 (0.78–1.00) 0.05
Discharge C-reactive protein (per mg/L) 1.00 (0.99–1.01) 0.70
Left ventricular systolic function < 40% 0.88 (0.52–1.49) 0.64
Discharge NYHA class≥III 0.97 (0.52–1.81) 0.92
BNP, B-type natriuretic peptide; CI, confidence interval; GDF-15, growth differentiation factor 15; HR, hazard ratio; NYHA, New York Heart
Association.
Table 4 Two-year mortality: multivariate model
HR (95% CI) P-value
Discharge GDF-15 and discharge BNP
GDF-15 < 3000 ng/mL and BNP < 1000 pg/mL (reference) 1
Only one of the variables above the mean 1.76 (0.99–3.14) 0.06
GDF-15 ≥ 3000 ng/mL and BNP ≥ 1000 pg/mL 4.33 (2.07–9.06) <0.001
Age (per year) 1.01 (0.99–1.04) 0.29
Male 1.52 (0.88–2.64) 0.13
Discharge creatinine (per mg/dL) 1.04 (0.72–1.48) 0.85
Discharge haemoglobin (per g/dL) 0.90 (0.80–1.02) 0.10
Discharge C-reactive protein (per mg/L) 1.00 (0.99–1.01) 0.66
Left ventricular systolic dysfunction < 40% 0.74 (0.42–1.28) 0.28
Discharge NYHA class ≥III 0.81 (0.43–1.53) 0.52
BNP, B-type natriuretic peptide; CI, confidence interval; GDF-15, growth differentiation factor 15; HR, hazard ratio; NYHA, New York Heart
Association.
Patients were cross-classified according to discharge BNP and discharge GDF-15.
Figure 1 Kaplan–Meier survival curves in patients with discharge growth
differentiation factor 15 (GDF-15) < 3000 and ≥ 3000 ng/mL. Patients
with elevated discharge GDF-15 had higher 2-year mortality.
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measured at baseline and after 12 months. Similar to the
study by Kempf et al., GDF-15 levels were associated with
features of advanced HF and other biomarkers of neurohor-
monal activation, inflammation, myocyte injury, and renal
dysfunction. In a multiple-variable Cox regression model that
included clinical risk factors, BNP, high-sensitivity C-reactive
protein, and high-sensitivity Troponin T, GDF-15 was an inde-
pendent death predictor. A recent report showed that
GDF-15 measured within or after an acute HF episode, when
included in a multi-marker approach (including N terminal pro
brain natriuretic peptide, high-sensitivity cardiac troponin T,
GDF-15, and soluble ST2) to determine prognosis, was associ-
ated with medium term mortality in acute HF patients.19 Our
study expands these previous observations in chronic and
acute HF patients, showing that GDF-15 is independently asso-
ciated with long-term mortality. Our results also hint that, by
using simultaneously BNP and GDF-15, a mortality risk gradi-
ent can be observed; suggesting that using both biomarkers,
we can identify patients in need of a closer follow-up. To the
best of our knowledge, this is the first study in which both
GDF-5 and BNP were considered for patient cross-
classification and their somehow synergic prognostic power
tested in a multivariate approach.
GDF-15 levels were equally elevated in patients with
preserved and reduced ejection fraction 3077.2 vs.
2980.1 ng/mL. This observation replicates other studies and
supports the important role of inflammation in HF with
preserved ejection fraction.7 In our patient population,
GDF-15 levels showed a positive correlation with C-reactive
protein. Patients with higher GDF-15 levels also tended to have
higher C-reactive protein, and, in fact, inflammatory markers
seem to be intimately associated with GDF-15. Previous obser-
vations have suggested an association of higher C-reactive pro-
tein levels with worse prognosis in acute HF, supporting the
role of inflammation in the pathophysiology of HF.20,21
Our study is limited by the relatively small sample size and
single centre nature. Despite the small sample size, we were
able to detect prognostic differences according to the dis-
charge GDF-15 level as well as to detect the added prognostic
value of GDF-15 on top of BNP knowledge. Future studies are
needed to extend our observations and to determine their
generalizability to other populations. We did not evaluate
other biomarkers with putative clinical value in the acute HF
setting such as high-sensivity troponin I and soluble ST2. Solu-
ble ST2 acts as a decoy receptor for interleukin-33, whose
binding exerts anti-inflammatory and anti-fibrotic effects.22,23
The elevation of soluble ST2 likely reflects activation of sys-
temic inflammation, and the knowledge of both GDF-15 and
soluble ST2 as different ways of reflecting a common inflam-
matory pathway would likely be interesting. Also, the use of
GDF-15 as a therapeutic target is yet unknown, and our results
do not have direct implications in the management of HF pa-
tients; still, a better risk stratification is crucial in HF approach.
Conclusions
The marker of inflammatory stress GDF-15 is associated with
long-term mortality in acute HF independently of and beyond
BNP. Thus, GDF-15, by reflecting increased wall stiffness from
inflammatory injury, may provide complementary pathophys-
iological information to that of BNP, which reflects haemody-
namic wall tension and stress. Our results suggest that the
inflammation-related marker GDF-15 may be a candidate to
future development of anti-inflammatory therapies for HF
patients.
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Figure 2 Kaplan–Meier survival curves according to discharge BNP and
growth differentiation factor 15 (GDF-15): reference category: both bio-
markers < mean; other categories—only one of the biomarkers ≥ mean
and both biomarkers ≥mean. Patients with both BNP and GDF-15<mean
had a clear survival benefit while those with both biomarkers ≥mean had
higher 2-year mortality.
GDF-15 in acute heart failure 1021
ESC Heart Failure 2018; 5: 1017–1022
DOI: 10.1002/ehf2.12301
References
1. Chow SL, Maisel AS, Anand I, Bozkurt B,
de Boer RA, Felker GM, Fonarow GC,
Greenberg B, Januzzi JL Jr, Kiernan
MS, Liu PP, Wang TJ, Yancy CW, Zile
MR. Role of biomarkers for the preven-
tion, assessment, and management of
heart failure: a scientific statement from
the American Heart Association. Circula-
tion 2017; 135: 1054–1091.
2. Bootcov MR, Bauskin AR, Valenzuela
SM, Moore AG, Bansal M, He XY, Zhang
HP, Donnellan M, Mahler S, Pryor K,
Walsh BJ, Nicholson RC, Fairlie WD,
Por SB, Robbins JM, Breit SN. MIC-1, a
novel macrophage inhibitory cytokine,
is a divergent member of the TGF-beta
superfamily. Proc Natl AcadSci U S A
1997; 94: 11514–11519.
3. Schlittenhardt D, Schober A, Strelau J,
Bonaterra GA, Schmiedt W, Unsicker K,
Metz J, Kinscherf R. Involvement
of growth differentiation factor15/
macrophage inhibitory cytokine-1
(GDF-15/MIC-1) in oxLDL-induced apo-
ptosis of human macrophages in vitro
and in arteriosclerotic lesions. Cell Tissue
Res 2004; 318: 325–333.
4. Kempf T, Eden M, Strelau J, Naguib M,
Willenbockel C, Tongers J, Heineke J,
Kotlarz D, Xu J, Molkentin JD, Niessen
HW, Drexler H, Wollert KC. The
transforming growth factor-beta super-
family member growth-differentiation
factor-15 protects the heart from
ischemia/reperfusion injury. Circ Res
2006; 98: 351–360.
5. Wollert KC, Kempf T, Wallentin L.
Growth differentiation factor 15 as a
biomarker in cardiovascular disease.
Clin Chem 2017; 63: 140–151.
6. Kempf, von Haehling S, Peter T, Allhoff
T, Cicoira M, Doehner W, Ponikowski P,
Filippatos GS, Rozentryt P, Drexler H,
Anker SD, Wollert KC. Prognostic utility
of growth differentiation factor-15 in pa-
tients with chronic heart failure. J Am
Coll Cardiol 2007; 50: 1054–1060.
7. Chan MM, Santhana Krishnan R, Chong
JP, Chen Z, Tai BC, Liew OW, Ng TP, Ling
LH, Sim D, Leong KT, Yeo PS, Ong HY,
Jaufeerally F, Wong RC, Chai P, Low AF,
Richards AM, Lam CS. Growth differen-
tiation factor 15 in heart failure with
preserved vs. reduced ejection fraction.
Eur J Heart Fail 2016; 18: 81–88.
8. Berger R, Huelsman M, Strecker K, Bojic
A, Moser P, Stanek B, Pacher R. B-type
natriuretic peptide predicts sudden
death in patients with chronic heart fail-
ure. Circulation 2002; 105: 2392–2397.
9. AnandIS, Fisher LD, Chiang YT, Latini R,
Masson S, Maggioni AP, Glazer RD,
Tognoni G, Cohn JN. For the Val-HeFT In-
vestigators. Changes in brain natriuretic
peptide and norepinephrine over time
and mortality and morbidity in the
Valsartan Heart Failure Trial (Val-HeFT).
Circulation 2003; 107: 1278–1283.
10. Doust JA, Pietrzak E, Dobson A, Glasziou
P. How well does B-type natriuretic pep-
tide predict death and cardiac events in
patients with heart failure: systematic
review. BMJ 2005; 330: 625.
11. Januzzi JL Jr, Sakhuja R, O’donoghue M,
Baggish AL, Anwaruddin S, Chae CU,
Cameron R, Krauser DG, Tung R,
Camargo CA Jr, Lloyd-Jones DM. Utility
of amino-terminal pro-brain natriuretic
peptide testing for prediction of 1-year
mortality in patients with dyspnea
treated in the emergency department.
Arch Intern Med 2006; 166: 315–320.
12. Bettencourt P, Azevedo A, Pimenta J,
Friões F, Ferreira S, Ferreira A. N-termi-
nal-pro-brain natriuretic peptide pre-
dicts outcome after hospital discharge
in heart failure patients. Circulation
2004; 110: 2168–2174.
13. Dickstein K, Cohen-Solal A, Filippatos G,
McMurray JJ, Ponikowski P, Poole-Wil-
son PA, Strömberg A, van Veldhuisen
DJ, Atar D, Hoes AW, Keren A, Mebazaa
A, Nieminen M, Priori SG, Swedberg K,
ESC Committee for Practice Guidelines
(CPG). ESC guidelines for the diagnosis
and treatment of acute and chronic
heart failure 2008: the Task Force for
the diagnosis and treatment of acute
and chronic heart failure 2008 of the
European Society of Cardiology. Devel-
oped in collaboration with the Heart
Failure Association of the ESC (HFA)
and endorsed by the European Society
of Intensive Care Medicine (ESICM).
Eur J Heart Fail 2008; 10: 933–989.
14. Frank D, Kuhn C, Brors B, Hanselmann
C, Ludde M, Katus HA, Frey N. Gene ex-
pression pattern in biomechanically
stretched cardiomyocytes: evidence for
a stretch-specific gene program. Hyper-
tension 2008; 51: 309–318.
15. Hagström E, Held C, Stewart RA,
Aylward PE, Budaj A, Cannon CP,
Koenig W, Krug-Gourley S, Mohler ER
3rd, Steg PG, Tarka E, Östlund O, White
HD, Siegbahn A, Wallentin L, Investiga-
tors STABILITY. Growth differentiation
factor 15 predicts all-cause morbidity
and mortality in stable coronary heart
disease. Clin Chem 2017; 631: 325–333.
16. Anand IS, Kempf T, Rector TS, Tapken
H, Allhoff T, Jantzen F, Kuskowski K,
Cohn JN, Drexler H, Wollert KC. Serial
measurement of growth-differentiation
factor-15 in heart failure: relation to dis-
ease severity and prognosis in the
Valsartan Heart Failure Trial. Circulation
2010; 122: 1387–1395.
17. Lok DJ, Klip IT, Lok SI, de la Porte
Bruggink-André PW, Badings E, van
Wijngaarden J, Voors AA, de Boer RA,
van Veldhuisen DJ, van der Meer P.
Incremental prognostic power of novel
biomarkers (growth-differentiation
factor-15, high-sensitivity C-reactive
protein, galectin-3, and high-sensitivity
troponin-T) in patients with advanced
chronic heart failure. Am J Cardiol
2013; 112: 831–837.
18. Hage C, Michaëlsson E, Linde C, Donal
E, Daubert JC, Gan LM, Lund LH. In-
flammatory biomarkers predict heart
failure severity and prognosis in patients
with heart failure with preserved ejec-
tion fraction. A holistic proteomic ap-
proach. Circ Cardiovasc Genet 2017; 10:
e001633.
19. Demissei BG, Cotter G, Prescott MF,
Felker GM, Filippatos G, Greenberg BH,
Pang PS, Ponikowski P, Severin TM,
Wang Y, Qian M, Teerlink JR, Metra M,
Davison BA, Voors AA. A multimarker
multi-time point-based risk stratification
strategy in acute heart failure: results
from the RELAX-AHF trial. Eur J Heart
Fail 2017; 19: 1001–1010.
20. Kalogeropoulos AP, Tang WH, Hsu A,
Felker GM, Hernandez AF, Troughton
RW, Voors AA, Anker SD, Metra M,
McMurray JJ, Massie BM, Ezekowitz
JA, Califf RM, O’Connor CM, Starling
RC, Butler J. High-sensitivity C-reactive
protein in acute heart failure: insights
from the ASCEND-HF trial. J Card Fail
2014; 20: 319–326.
21. Villacorta H, Masetto AC, Mesquita ET.
C-reactive protein: an inflammatory
marker with prognostic value in patients
with decompensated heart failure. Arq
Bras Cardiol 2007; 88: 585–589.
22. Januzzi JL Jr. ST2 as a cardiovascular
risk biomarker: from the bench to the
bedside. J Cardiovasc Transl Res 2013;
6: 493–500.
23. Wang TJ, Wollert KC, Larson MG,
Coglianese E, McCabe EL, Cheng S, Ho
JE, Fradley MG, Ghorbani A, Xanthakis
V, Kempf T, Benjamin EJ, Levy D, Vasan
RS, Januzzi JL. Prognostic utility of
novel biomarkers of cardiovascular
stress: the Framingham Heart Study.
Circulation 2012; 126: 1596–1604.
1022 P. Bettencourt et al.
ESC Heart Failure 2018; 5: 1017–1022
DOI: 10.1002/ehf2.12301
